Taysha Gene Therapies Inc · Q2 2022 earnings

Briefing

Reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Taysha Gene Therapies reported progress in giant axonal neuropathy (GAN) with TSHA-120, demonstrating durable neurophysiological improvements. Positive feedback from MHRA supports regulatory strategy and manufacturing approach. Preclinical data for TSHA-102 in Rett syndrome showed near normalization of survival and behavior in neonatal knockout Rett mice.

• TSHA-120-treated patients with GAN demonstrated durable neurophysiological improvements in the sensory nerve action potential (SNAP), a definitive clinical endpoint, compared to rapid and irreversible decline in sensory function early in life in untreated patients based on natural history.
• Pathology from nerve biopsies in all evaluable samples confirmed the presence of regenerative nerve fibers in 100% of TSHA-120-treated patients (n=11).
• TSHA-120 commercial grade and clinical trial material considered comparable across all key quality attributes as assessed by an extensive panel of release assays and next-generation sequencing.
• Late-breaking positive preclinical data for TSHA-102 in Rett syndrome demonstrated near normalization of survival and normalization of behavior in neonatal knockout Rett mice, a model significantly more severe than the human phenotype

Headline financials

Revenue & EPS history

Taysha anticipates further regulatory update, including from FDA, for TSHA-120 in GAN and first-in-human preliminary Phase 1/2 data for TSHA-102 in Rett syndrome by year-end 2022.